RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Coherus BioSciences Stock

Coherus BioSciences Equity 2024

Coherus BioSciences Equity

0 USD

Ticker

CHRS

ISIN

US19249H1032

WKN

A12ETZ

In 2024, Coherus BioSciences's equity was 0 USD, a 0% increase from the 0 USD equity in the previous year.

Coherus BioSciences Aktienanalyse

What does Coherus BioSciences do?

Coherus BioSciences Inc is a pharmaceutical company specializing in the development and marketing of biosimilars. The company was founded in California in 2010 and has since focused on the development of biopharmaceuticals. Coherus BioSciences Inc's history began with the acquisition of the biomanufacturing facility from PDL BioPharma, a company specialized in the development and marketing of therapeutics and biologics. Coherus BioSciences Inc used the facility to build a portfolio of biosimilars. Coherus BioSciences Inc's business model is based on the sale of biosimilars, which offer a cost-effective alternative to expensive biologics. Biosimilars are biopharmaceuticals that are manufactured similarly to already approved biologics, but can be offered at a lower price. Coherus BioSciences Inc specializes in the development and marketing of biosimilars in the fields of oncology, immunology, and neurology. The products that the company currently brings to market or is developing include biosimilar versions of Enbrel, Neulasta, and Humira. Enbrel is a biologic used to treat rheumatoid arthritis, psoriasis, and other inflammatory conditions. Neulasta is a medication used to support white blood cells after chemotherapy, while Humira is a medication used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. Coherus BioSciences Inc has also launched a collaboration with Novartis to develop a biosimilar version of Lucentis. Lucentis is a biologic used to treat age-related macular degeneration. Overall, Coherus BioSciences Inc has built a portfolio of ten biosimilars and is working to bring more products to market. The company has also conducted several preclinical and clinical studies to demonstrate the efficacy and safety of its biosimilars. Coherus BioSciences Inc is headquartered in Redwood City, California. The company currently employs over 140 employees and has offices in the USA, Europe, and Asia. Overall, Coherus BioSciences Inc has played a groundbreaking role in the development of cost-effective biosimilars. The company specializes in the marketing of biosimilars and offers a range of products in the fields of oncology, immunology, and neurology. Coherus BioSciences Inc has also launched a collaboration with another company to develop a biosimilar version of Lucentis. The company has built a portfolio of ten biosimilars and is constantly expanding its offerings. Coherus BioSciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Coherus BioSciences's Equity

Coherus BioSciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Coherus BioSciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Coherus BioSciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Coherus BioSciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Coherus BioSciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Coherus BioSciences stock

What is the equity of Coherus BioSciences this year?

Coherus BioSciences has equity of 0 USD this year.

What was the equity of Coherus BioSciences compared to the previous year?

The equity of Coherus BioSciences has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Coherus BioSciences?

A high equity is advantageous for investors of Coherus BioSciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Coherus BioSciences?

A low equity can be a risk for investors of Coherus BioSciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Coherus BioSciences affect the company?

An increase in equity of Coherus BioSciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Coherus BioSciences affect the company?

A reduction in equity of Coherus BioSciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Coherus BioSciences?

Some factors that can affect the equity of Coherus BioSciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Coherus BioSciences so important for investors?

The equity of Coherus BioSciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Coherus BioSciences take to change the equity?

To change equity, Coherus BioSciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Coherus BioSciences pay?

Over the past 12 months, Coherus BioSciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Coherus BioSciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Coherus BioSciences?

The current dividend yield of Coherus BioSciences is .

When does Coherus BioSciences pay dividends?

Coherus BioSciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Coherus BioSciences?

Coherus BioSciences paid dividends every year for the past 0 years.

What is the dividend of Coherus BioSciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Coherus BioSciences located?

Coherus BioSciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Coherus BioSciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Coherus BioSciences from 11/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/28/2024.

When did Coherus BioSciences pay the last dividend?

The last dividend was paid out on 11/28/2024.

What was the dividend of Coherus BioSciences in the year 2023?

In the year 2023, Coherus BioSciences distributed 0 USD as dividends.

In which currency does Coherus BioSciences pay out the dividend?

The dividends of Coherus BioSciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Coherus BioSciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Coherus BioSciences

Our stock analysis for Coherus BioSciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Coherus BioSciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.